MENLO PARK, Calif., Aug. 8, 2018 /PRNewswire/ -- Gala Therapeutics (Gala), a clinical-stage developer of medical devicesto treat pulmonary disease, today announced that data from a Late-Breaking Abstract from a first-in-human study of the Rheox™ system will be presented at the European Respiratory Society (ERS) in Paris, France on
"We look forward to sharing initial data from our Chronic Bronchitis program in an oral presentation at ERS, one of the premier academic forums for interventional pulmonology," said Jonathan Waldstreicher, MD and CEO of Gala. "We have accomplished what drugs have not by developing a medical device to directly treat the mucus-producing cells in the airways that cause debilitating cough and mucus symptoms. With this data, Gala is at the forefront of the next generation of targeted Interventional Pulmonary technologies, offering clinically meaningful outcomes to patients."
About Gala Therapeutics
Gala Therapeutics is a privately-held medical device company based in Menlo Park, CA that was formed by Apple Tree Partners, a life-sciences focused venture capital firm based in New York. Gala is dedicated to developing disease modifying therapies that improve survival, quality of life, and outcomes for patients with lung cancer, COPD, asthma, and other pulmonary diseases. Gala is building a portfolio of technologies to address the needs of interventional pulmonologists, thoracic surgeons, and all physicians who treat pulmonary disease.
View original content:http://www.prnewswire.com/news-releases/data-from-first-in-human-rheox-bronchial-rheoplasty-trial-to-be-presented-at-the-european-respiratory-society-300694399.html
SOURCE Gala Therapeutics
Subscribe to our Free Newsletters!